We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+26.16%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$60.9M
Cap. Flow
-$112M
Cap. Flow %
-40.48%
Top 10 Hldgs %
46.86%
Holding
81
New
21
Increased
12
Reduced
18
Closed
29

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$16.6M
2
COR icon
Cencora
COR
+$7.84M
3
SNN icon
Smith & Nephew
SNN
+$7.09M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$6.82M
5
ACH
Accendra Health
ACH
+$5.26M

Top Sells

Rank Stock Value
1
EHC icon
Encompass Health
EHC
+$15M
2
IART icon
Integra LifeSciences
IART
+$13.3M
3
AHCO icon
AdaptHealth
AHCO
+$11.4M
4
ABBV icon
AbbVie
ABBV
+$11M
5
BMY icon
Bristol-Myers Squibb
BMY
+$8.98M

Sector Composition

Rank Sector Weight
1 Healthcare 93.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$28.7B
$4.14M 1.49%
124,323
-19,990
-14% -$730K
LH icon
27
Labcorp
LH
$25.6B
$4.04M 1.46%
+23,087
New +$3.99M
STRO icon
28
Sutro Biopharma
STRO
$400M
$3.73M 1.35%
17,205
-29,012
-63% -$4.8M
MBIO icon
29
Mustang Bio
MBIO
$4.36M
$3.38M 1.22%
1,189
-708
-37% -$1.69M
GDRX icon
30
GoodRx Holdings
GDRX
$1.26B
$3.12M 1.13%
+77,379
New +$3.55M
HUM icon
31
Humana
HUM
$44.1B
$3.08M 1.11%
+7,504
New +$3.12M
RNAC icon
32
Cartesian Therapeutics
RNAC
$257M
$3M 1.08%
33,019
-17,383
-34% -$1.51M
AZN icon
33
AstraZeneca
AZN
$250B
$2.84M 1.03%
+28,446
New +$3.01M
ANGO icon
34
AngioDynamics
ANGO
$625M
$2.83M 1.02%
+184,901
New +$2.35M
PRAH
35
DELISTED
PRA Health Sciences, Inc.
PRAH
$2.71M 0.98%
+21,590
New +$2.41M
IOVA icon
36
Iovance Biotherapeutics
IOVA
$2.77B
$2.52M 0.91%
+54,221
New +$2.15M
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$5.97B
$2.36M 0.85%
133,648
+16,168
+14% +$284K
CNC icon
38
Centene
CNC
$31.7B
$2.3M 0.83%
38,313
-36,095
-49% -$2.29M
IMUX icon
39
Immunic
IMUX
$198M
$2.12M 0.76%
13,861
+2,770
+25% +$497K
ZTS icon
40
Zoetis
ZTS
$32.4B
$2.1M 0.76%
12,691
-34,269
-73% -$5.57M
APTO
41
DELISTED
Aptose Biosciences, Inc.
APTO
$2.09M 0.75%
1,062
+295
+38% +$693K
EUCRU
42
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.08M 0.75%
+195,000
New +$1.98M
PRTA icon
43
Prothena Corp
PRTA
$449M
$1.82M 0.66%
151,820
-110,953
-42% -$1.31M
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$1.59M 0.57%
42,292
-9,839
-19% -$358K
MRK icon
45
Merck
MRK
$317B
$1.22M 0.44%
+15,635
New +$1.2M
QTNT
46
DELISTED
Quotient Limited Ordinary Shares
QTNT
$1.18M 0.43%
+5,665
New +$1.32M
PNTG icon
47
Pennant Group
PNTG
$1.36B
$1.06M 0.38%
18,227
+4,528
+33% +$218K
MDVL
48
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$955K 0.34%
+1,269
New +$887K
AKTX
49
Akari Therapeutics
AKTX
$14.1M
$382K 0.14%
+258
New +$357K
SLDB icon
50
Solid Biosciences
SLDB
$857M
$346K 0.12%
+3,045
New +$193K
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Endurant Capital Management held 81 positions worth $277M, down 18% from $338M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Endurant Capital Management withdrew a net $112M in Q4 2020, closing 29 positions and reducing 18 holdings. Its most notable exit was Integra LifeSciences, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 83% a quarter earlier.

Against the trend, Endurant Capital Management opened a new position in Becton Dickinson worth $17.3M.

  • Endurant Capital Management's largest Q4 2020 buy was Becton Dickinson: 70,996 shares worth $17.3M.
  • Endurant Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q4 2020, an estimated $6.82M increase.
  • Endurant Capital Management's biggest Q4 2020 reduction was Encompass Health, cutting an estimated $15M.
  • Endurant Capital Management fully exited Integra LifeSciences in Q4 2020, selling an estimated $13.3M.
  • Endurant Capital Management's ten largest holdings make up 47% of its $277M portfolio in Q4 2020.
  • Endurant Capital Management opened 21 new positions and closed 29 in Q4 2020.
  • Endurant Capital Management's portfolio value fell 18% quarter-over-quarter to $277M.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.